A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-05-03
Adverse events
Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-04 (study day 79); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 318); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-04-24 (study day 343); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-07-02 (study day 412); relationship: Y
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-10-23 (study day 525); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2025-01-03 (study day 597); relationship: not assessed
Data queries
No data queries.